Eli Lilly's Strategic Pivot: Oncology Ambitions and Weight-Loss Nuances

Eli Lilly nears a $2B+ acquisition of Kelonia for CAR-T therapies, diversifying from its weight-loss drugs as new data reveals a muscle-loss challenge for tirzepatide.

Eli Lilly is placing a massive, forward-looking bet on next-generation cancer therapies. The pharmaceutical giant is in advanced talks to acquire Kelonia Therapeutics for a deal valued at over $2 billion, according to reports from the Wall Street Journal and CNBC. This potential acquisition, which could be announced imminently, represents a staggering premium for a company whose lead candidate is only in Phase 1 trials and was valued at roughly $100 million in 2022. The deal is expected to include milestone payments tied to future clinical successes.

This move signals a determined effort to diversify beyond its dominant diabetes and obesity business. The company’s oncology division generated $9.4 billion in revenue in 2025, accounting for approximately 15% of its total $65.2 billion in sales. The Kelonia deal follows the recent $300 million acquisition of CrossBridge Bio, underscoring Lilly’s push to build a stronger position in hematology-oncology, where cell and gene therapies are reshaping the field.

Kelonia’s focus is on developing CAR-T cell therapies, which involve reprogramming a patient’s own immune cells to recognize and attack cancer cells. Its lead candidate targets multiple myeloma, a blood cancer, with an ongoing Phase 1 study designed for up to 40 participants.

Meanwhile, the company’s core weight-loss portfolio is under a new microscope. Recent comparative data reveals a nuanced challenge for its blockbuster drug, tirzepatide. While patients lose more weight on tirzepatide than on Novo Nordisk’s rival Wegovy, they also lose an average of two percent more muscle mass after one year. The Wegovy group showed no significant difference from a placebo in muscle loss, potentially giving competitors a new marketing angle focused on the quality of weight reduction.

On the commercial front, Eli Lilly is advancing its oral obesity treatment, Foundayo. The drug, priced at $149 per month, recently launched in the United Arab Emirates and is available in the US, where it recorded around 1,390 prescriptions in its first week of availability. Its key advantage is that it can be taken with food, unlike other oral medications requiring an empty stomach. However, the US Food and Drug Administration has requested additional safety data for the treatment. Positively, the ACHIEVE-4 study demonstrated cardiovascular benefits, providing a counter-argument to Novo Nordisk.

Looking beyond its drug pipeline, Eli Lilly is addressing its substantial manufacturing energy needs. The company is exploring the construction of small modular nuclear reactors in partnership with the state of Indiana, aiming for long-term carbon-neutral production.

The stock market has yet to reward this broad strategic offensive. Eli Lilly’s shares trade at around EUR 785, marking a decline of nearly 15% since the start of the year and placing the price noticeably below its 50-day moving average. Investor attention now turns to the company’s first-quarter 2026 earnings report on April 30th, which will provide early commercial metrics for Foundayo and detail integration costs for recent acquisitions. For the full year, management maintains an earnings per share guidance range of $33.50 to $35.00.

Upcoming catalysts are plentiful. In the second quarter of 2026, Eli Lilly will submit data from the ACHIEVE-4 diabetes study to US regulators. Furthermore, results from seven Phase 3 trials for its next hopeful obesity drug, retatrutide, are expected before year-end.